Atopic Dermatitis Research Articles

Predicting airway hyperresponsiveness to methacholine in patients with atopic dermatitis.

Predicting airway hyperresponsiveness to methacholine in patients with atopic dermatitis.

Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors.

Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed. This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based recommendations. The Patient characteristics, type of Intervention, Control, and Outcome framework was used to determine 48 questions related to AD management. Evidence was graded, recommendations were determined, and, after 2 voting rounds among the Korean Atopic Dermatitis Association (KADA) council members, consensus was achieved. This guideline provides treatment guidance on advanced systemic treatment modalities for AD. In particular, the guideline offers up-to-date treatment recommendations for biologics and Janus-kinase inhibitors used in the treatment of patients with moderate to severe AD. It also provides guidance on other therapies for AD, along with tailored recommendations for children, adolescents, the elderly, and pregnant or breastfeeding women. KADA's updated AD treatment guidelines incorporate the latest evidence and expert opinion to provide a comprehensive approach to AD treatment. The guidelines will help clinicians optimize patient-specific therapies.

Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy.

Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed. This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based practices. The Patient characteristics, type of Intervention, Control, and Outcome framework was used to determine 48 questions related to AD management. Evidence was graded, recommendations were determined, and, after 2 voting rounds among the Korean Atopic Dermatitis Association (KADA) council members, consensus was achieved. The guidelines provide detailed recommendations on foundational therapies, including the use of moisturizers, cleansing and bathing practices, allergen avoidance, and patient education. Guidance on topical therapies, such as topical corticosteroids and calcineurin inhibitors, is also provided to help manage inflammation and maintain skin barrier function in patients with AD. Additionally, recommendations on conventional systemic therapies, including corticosteroids, cyclosporine, and methotrexate, are provided for managing moderate to severe AD. KADA's updated AD guidelines offer clinicians evidence-based strategies focused on basic therapies, topical therapies, and conventional systemic therapies, equipping them to enhance quality of care and improve patient outcomes in AD management.

An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms.

An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms.

Inflammation dynamics of atopic dermatitis: Phase transition and scaling law of remission time.

Inflammation dynamics of atopic dermatitis: Phase transition and scaling law of remission time.

Investigating the role of mosquito repellents in atopic dermatitis.

Investigating the role of mosquito repellents in atopic dermatitis.

Targeted Therapy for Atopic Dermatitis: A Novel Approach

Abstract: Atopic Dermatitis (AD) is a chronic, inflammatory, and widespread skin disease with heterogeneous manifestations having a significant influence on the lives of youngsters and adults. Atopic Dermatitis prevalence is higher in African-American children compared with European American children, and the interaction between various factors such as genetics, skin barrier dysfunction, and immune abnormalities mainly causes it. Despite various available treatment options for atopic dermatitis, they often fall short in addressing the root cause, prompting patients to seek more effective and enduring solutions. To combat these shortcomings, researchers are focusing on the development of targeted therapy. The development of targeted treatment options involves the utilization of a range of biological agents designed to pinpoint specific components and regulators of inflammatory pathways associated with allergic and inflammatory conditions. Phytochemicals, viz. alkaloids, phenols, carotenoids, and organo-sulphurs, have been utilized in traditional medicine for centuries, which contribute to increased efficacy while minimizing adverse events. The objective of this review is to give information about the epidemiology, pathophysiology, and evolving landscape of targeted therapy for atopic dermatitis, encompassing both biologics and phytochemicals.

0122 Transfer learning to integrate multiomic data to enhance nemolizumab response assessment in atopic dermatitis and prurigo nodularis

0122 Transfer learning to integrate multiomic data to enhance nemolizumab response assessment in atopic dermatitis and prurigo nodularis

0126 Spatial and single cell proteomic analysis reveal alterations in type2 inflammation in prurigo nodularis and atopic dermatitis

0126 Spatial and single cell proteomic analysis reveal alterations in type2 inflammation in prurigo nodularis and atopic dermatitis

0600 Distinct epidermal cell populations and single-cell gene expression signatures are associated with staphylococcus aureus in atopic dermatitis

0600 Distinct epidermal cell populations and single-cell gene expression signatures are associated with staphylococcus aureus in atopic dermatitis

0072 Single-cell transcriptome reveals keratinocyte subclusters that contribute to altered differentiation and inflammatory responses in atopic dermatitis

0072 Single-cell transcriptome reveals keratinocyte subclusters that contribute to altered differentiation and inflammatory responses in atopic dermatitis

0330 Emotion and behavior in children with atopic dermatitis: Comparing teacher and parent reports

0330 Emotion and behavior in children with atopic dermatitis: Comparing teacher and parent reports

0157 Interaction between adipocyte lineage cells and mast cells contributes skin inflammation and fibrosis in atopic dermatitis

0157 Interaction between adipocyte lineage cells and mast cells contributes skin inflammation and fibrosis in atopic dermatitis

LB1125 Real-world evaluation of efficacy and safety of abrocitinib in moderate-to-severe atopic dermatitis across a multi-site hospital system

LB1125 Real-world evaluation of efficacy and safety of abrocitinib in moderate-to-severe atopic dermatitis across a multi-site hospital system

0595 The effects of topical antimicrobial-corticosteroid combination therapy in comparison to topical steroids alone on the skin microbiome of patients with atopic dermatitis

0595 The effects of topical antimicrobial-corticosteroid combination therapy in comparison to topical steroids alone on the skin microbiome of patients with atopic dermatitis

0998 Serum proteomic profiling of patients with immune checkpoint inhibitor-associated eczematous dermatitis highlights therapeutic targets and immunologic distinctions from atopic dermatitis

0998 Serum proteomic profiling of patients with immune checkpoint inhibitor-associated eczematous dermatitis highlights therapeutic targets and immunologic distinctions from atopic dermatitis

Epigenetics of atopic dermatitis: pathogenesis and therapeutic prospects.

Epigenetics of atopic dermatitis: pathogenesis and therapeutic prospects.

0692 Evaluation of clinical scales among populations diagnosed with atopic dermatitis: A scoping review

0692 Evaluation of clinical scales among populations diagnosed with atopic dermatitis: A scoping review

LB1144 Treatment-free disease control after tralokinumab in patients with moderate-to-severe atopic dermatitis

LB1144 Treatment-free disease control after tralokinumab in patients with moderate-to-severe atopic dermatitis

0046 CD1a-targeted PD-1 agonists for localized immunosuppression in atopic dermatitis

0046 CD1a-targeted PD-1 agonists for localized immunosuppression in atopic dermatitis